After the multiple myeloma CAR-T therapy approval, eyes will now be on the FDAs decision regarding Opdivos use for additional indications, as well as Zeposia in ulcerative colitis. Abecma was being developed by Bristol Myers Squibb and bluebird bio Inc. CAR-T therapy refers to extraction of a patients own T cells, which are then genetically modified and infused back into the patients body. Crown Crafts Inc designs, markets and distributes infant, toddler and juvenile consumer products. That said, the recent approval marks the only approved CAR-T therapy for the treatment of multiple myeloma. These T-Cells target and destroy any abnormal cells, including cancer cells.
Abecma is a targeted medication.
( z0 medication :name ( z1 name :op "Abecma" ) :ARG1-of ( z2 target ) )
(z0 / medication
    :name (z1 / name
              :op1 "Abecma")
    :ARG1-of (z2 / target-01))
Abecma is a targeted medication .
z1 :op1 0
z0 :ARG1-of z2
z0 :name z1